NeuroPace (NPCE) EBT Growth (1y) (2021 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -18.50% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 11.26% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | -8.83% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 44.35% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 5.78% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 103.34% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 74.66% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -27.02% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 54.33% |
| 10 | NeuroPace | 558.86 Mn | 504.88 Mn | 18.05 Mn | -0.26% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.26% |
| Dec 31, 2025 | 47.15% |
| Sep 30, 2025 | 36.91% |
| Jun 30, 2025 | -6.96% |
| Mar 31, 2025 | 27.51% |
| Dec 31, 2024 | 20.12% |
| Sep 30, 2024 | 23.07% |
| Jun 30, 2024 | 17.43% |
| Mar 31, 2024 | 6.09% |
| Dec 31, 2023 | 41.23% |
| Sep 30, 2023 | 36.89% |
| Jun 30, 2023 | 26.65% |
| Mar 31, 2023 | 16.58% |
| Dec 31, 2022 | -2.89% |
| Sep 30, 2022 | -47.26% |
| Jun 30, 2022 | -97.63% |
| Mar 31, 2022 | -101.12% |
| Dec 31, 2021 | -119.80% |
| Sep 30, 2021 | -100.43% |
| Jun 30, 2021 | 12.14% |
| Mar 31, 2021 | 32.63% |